ChemoCentryx, Inc

Short Term Long Term Short Term Comparison Long Term Comparison
  • CCXI
  • 1d0.06%
  • 1w0.02%
  • 1m0.68%
  • 1y50.39%
ATH
  • ATH Price$68.40
  • ATH Date2021-03-01
  • % since ATH-23.99%
  • % to ATH31.56%
ATL
  • ATL Price$2.03
  • ATL Date2016-05-06
  • % from ATL2,461.08%
  • Last Low Price$9.59
  • Last Low Date2021-05-21
  • % From Last Low442.13%
IPO
  • IPO Price$10.49
  • % Current ROI USD495.61%
  • ATH Price$68.40
  • % ROI ATH 336,945.81%
[addtoany]

Graph takes few seconds to load...

[financial_chart symbol="CCXI"]

Key Data [addtoany]

Current price $51.99
Sector Healthcare
Industry Biotechnology
Today's High/Low $51.99/$51.99
Volume 0.00
Previous Close $51.96
52 Week High/Low $52/$14.95
Market Cap 3,739,105,024.00
P/E Ratio 0
Forward P/E 1 Yr. $0.00
Earnings Per Share(EPS) $-0.66
Annualized Dividend $0
$51.99
[addtoany]

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.
It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy.
The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease.
In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in San Carlos, California.

Annual Data | Millions of US $ except per share data
Cash on hand
Receivables
Inventory
Pre-Paid Expenses
Other Current Assets
Total Current Assets
Property, Plant, And Equipment
Long-Term Investments
Goodwill And Intangible Assets
Other Long-Term Assets
Total Long-Term Assets
Total Assets
Total Current Liabilities
Long Term Debt
Other Non-Current Liabilities
Total Long Term Liabilities
Total Liabilities
Common Stock Net
Retained Earnings (Accumulated Deficit)
Comprehensive Income
Other Share Holders Equity
Share Holder Equity
Total Liabilities And Share Holders Equity